News
-
-
PRESS RELEASE
Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive® and Baiama® are now available in the European Union
Formycon expands commercial portfolio with the launch of Aflibercept biosimilars Ahzantive(R) and Baiama(R) in the European Union, reinforcing market penetration and growth strategy -
-
PRESS RELEASE
Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
Formycon AG reports successful financial year 2025 with operational progress, market growth, and strategic partnerships. Forecast for 2026 includes revenue growth and positive EBITDA -
-
PRESS RELEASE
Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026
Formycon AG to hold Conference Call on Results of FY 2025 and participate in international Investor Conferences in Q2 2026. Details and registration at provided links -
-
-
-
PRESS RELEASE
Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
